No registrations found.
ID
Source
Brief title
Health condition
Postmenopausal Osteoporosis, tolerability, efficacy, Bisfosfonates
Osteoporose, tolerantie, werkzaamheid, bisfofonaten
Sponsors and support
Intervention
Outcome measures
Primary outcome
Vergelijken van tolerantie en effectiviteit (dmv van vragenlijsten en botmarkers) van specialite alendronate ten opzichte van generiek alendronate.
Secondary outcome
Geen.
Background summary
Study Title:
Comparison of tolerability and efficacy of brand versus generic alendronate.
Objectives:
Evaluation of difference in tolerability and efficacy as measured by bone markers between generic versus brand alendronate in postmenopausal women with osteoporosis.
Design and Outcomes:
A randomized single centre cross-over study to test the tolerability and efficacy of brand compared to generic alendronate in postmenopausal women with established osteoporosis. Tolerability is evaluated by the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire. Medication use and adherence is evaluated by the Self-efficacy for Appropriate Medication Use (SEAMS) Questionnaire and the Brief Medication Questionnaire (BMQ). Efficacy is evaluated by the assessment of bone-markers.
Interventions and Duration:
After randomization, patients start with generic alendronate or brand oral alendronate once weekly in a single blinded, open label setting. After the first period of 12 weeks, there is a cross-over to branded and generic oral alendronate once weekly respectively. Evaluation of tolerability, adherence and efficacy is planned at week 6, 12, 18 and 24. After the study period of 24 weeks patients will continue treatment with the alendronate formulation they prefer, according to current practice.
Sample Size and Population:
30 postmenopausal women with osteoporosis defined as a DEXA T-score <-2,5 SD and/or ¡Ý 1 vertebral fracture.
Study objective
Evaluation of difference in tolerability and efficacy as measured by bonemarkers between generic versus brand alendronate in postmenopausal women with osteoporosis.
Study design
Na screeningsperiode van max 89 dagen (max 2 visits) behandelperiode: 24 weken met op week 12 cross-over; in totaal 2 visits.
Intervention
Lichamelijk onderzoek, interview, bloed en urine onderzoek, invullen vragenlijsten.
J.P.W. Bergh, van den
Venlo 5912 BL
The Netherlands
+31 (0)77-3205555
jvdbergh@viecuri.nl
J.P.W. Bergh, van den
Venlo 5912 BL
The Netherlands
+31 (0)77-3205555
jvdbergh@viecuri.nl
Inclusion criteria
1. Postmenopausal women 50 yrs or >;
2. Diagnosed with osteoporosis as defined by: DEXA: T-score of-2.5 at lumbar spine or femoral neck os total hip, and or a vertebral fracture;
3. No treatment for osteoporosis in the 12 month before inclusion;
4. Ability to understand study procedures and to comply with them for the entire lenght of the study.
Exclusion criteria
1. Patients with prior teratment of osteoporosis (bisfofonates, testosterone, hormone replacement therapy( HRT) , selective estrogen receptor modulators ( SERMs) or calcitonin);
2. Patients who are previously intolerant of bisfosfonates;
3. Patients with disorders of esophageal motility or in whom oral bisfosfonates are contraindicated;
4. A history of upper GI tract disorder other than esophageal motility disorder is not a reason for exclusion.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL1757 |
| NTR-old | NTR1867 |
| Other | Viecuri MC : 09-016 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |